265 related articles for article (PubMed ID: 26660529)
1. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.
Vemer P; Corro Ramos I; van Voorn GA; Al MJ; Feenstra TL
Pharmacoeconomics; 2016 Apr; 34(4):349-61. PubMed ID: 26660529
[TBL] [Abstract][Full Text] [Related]
2. Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.
de Boer PT; Frederix GW; Feenstra TL; Vemer P
Pharmacoeconomics; 2016 Sep; 34(9):833-45. PubMed ID: 27129572
[TBL] [Abstract][Full Text] [Related]
3. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool.
Briggs ADM; Wolstenholme J; Scarborough P
BMC Health Serv Res; 2019 Jul; 19(1):489. PubMed ID: 31307459
[TBL] [Abstract][Full Text] [Related]
5. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
6. TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility.
Büyükkaramikli NC; Rutten-van Mölken MPMH; Severens JL; Al M
Pharmacoeconomics; 2019 Nov; 37(11):1391-1408. PubMed ID: 31705406
[TBL] [Abstract][Full Text] [Related]
7. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
Kent S; Becker F; Feenstra T; Tran-Duy A; Schlackow I; Tew M; Zhang P; Ye W; Lizheng S; Herman W; McEwan P; Schramm W; Gray A; Leal J; Lamotte M; Willis M; Palmer AJ; Clarke P
Pharmacoeconomics; 2019 Nov; 37(11):1305-1312. PubMed ID: 31347104
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
9. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
10. Four Aspects Affecting Health Economic Decision Models and Their Validation.
Feenstra T; Corro-Ramos I; Hamerlijnck D; van Voorn G; Ghabri S
Pharmacoeconomics; 2022 Mar; 40(3):241-248. PubMed ID: 34913142
[TBL] [Abstract][Full Text] [Related]
11. A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data.
Corro Ramos I; van Voorn GAK; Vemer P; Feenstra TL; Al MJ
Value Health; 2017 Sep; 20(8):1041-1047. PubMed ID: 28964435
[TBL] [Abstract][Full Text] [Related]
12. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
Cooper NJ; Sutton AJ; Abrams KR
Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
[TBL] [Abstract][Full Text] [Related]
14. The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.
van Voorn GA; Vemer P; Hamerlijnck D; Ramos IC; Teunissen GJ; Al M; Feenstra TL
Appl Health Econ Health Policy; 2016 Apr; 14(2):129-33. PubMed ID: 26385585
[TBL] [Abstract][Full Text] [Related]
15. [Decision analytic modeling and their impact on health care decision making].
Inotai A; Kaló Z; Mészáros A
Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
[TBL] [Abstract][Full Text] [Related]
16. Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making.
Drummond M; Brown R; Fendrick AM; Fullerton P; Neumann P; Taylor R; Barbieri M;
Value Health; 2003; 6(4):407-16. PubMed ID: 12859580
[TBL] [Abstract][Full Text] [Related]
17. The role of decision analytic modeling in the health economic assessment of spinal intervention.
Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
[TBL] [Abstract][Full Text] [Related]
18. [Aspects of economic evaluation in health care].
Noelle G; Jaskulla E; Sawicki PT
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):28-33. PubMed ID: 16341607
[TBL] [Abstract][Full Text] [Related]
19. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
20. A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations.
Wang J; Pouwels X; Ramaekers B; Frederix G; van Lieshout C; Hoogenveen R; Li X; de Wit GA; Joore M; Koffijberg H; van Giessen A; Knies S; Feenstra T;
Pharmacoeconomics; 2024 Jul; 42(7):797-810. PubMed ID: 38613660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
